These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 1645988)
1. Cisplatin-induced peripheral neurotoxicity: relationship to dose intensity. Pollera CF; Pietrangeli A; Giannarelli D Ann Oncol; 1991 Mar; 2(3):212. PubMed ID: 1645988 [No Abstract] [Full Text] [Related]
2. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer. Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221 [TBL] [Abstract][Full Text] [Related]
3. Peripheral neurotoxicity following high-dose cisplatin with glutathione: clinical and neurophysiological assessment. Pirovano C; Balzarini A; Böhm S; Oriana S; Spatti GB; Zunino F Tumori; 1992 Aug; 78(4):253-7. PubMed ID: 1334604 [TBL] [Abstract][Full Text] [Related]
5. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cavaletti G; Marzorati L; Bogliun G; Colombo N; Marzola M; Pittelli MR; Tredici G Cancer; 1992 Jan; 69(1):203-7. PubMed ID: 1309303 [TBL] [Abstract][Full Text] [Related]
6. High-dose (200 mg/m2) cisplatin-induced neurotoxicity in primary advanced ovarian cancer patients. Panici PB; Greggi S; Scambia G; Di Roberto P; Iacobelli S; Mancuso S Cancer Treat Rep; 1987 Jun; 71(6):669-70. PubMed ID: 3034424 [No Abstract] [Full Text] [Related]
7. A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC). Bacon M; James K; Zee B Int J Gynecol Cancer; 2003; 13(4):428-34. PubMed ID: 12911718 [TBL] [Abstract][Full Text] [Related]
8. Lhermitte's sign following oxaliplatin-containing chemotherapy in a cisplatin-pretreated ovarian cancer patient. Ciucci G; De Giorgi U; Leoni M; Bianchedi G Eur J Neurol; 2003 May; 10(3):328-9. PubMed ID: 12752412 [No Abstract] [Full Text] [Related]
9. High-dose cisplatin-related peripheral neuropathy. Ostchega Y; Donohue M; Fox N Cancer Nurs; 1988 Feb; 11(1):23-32. PubMed ID: 2834044 [No Abstract] [Full Text] [Related]
10. [Peripheral neuropathy produced by cisplatin]. Valero Jiménez P; Murillo Capitán E; Sánchez Romero JA; Arbizu Ladrón de Guevara ML Rev Esp Oncol; 1984; 31(3):511-3. PubMed ID: 6085937 [TBL] [Abstract][Full Text] [Related]
13. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. Postma TJ; Hoekman K; van Riel JM; Heimans JJ; Vermorken JB J Neurooncol; 1999; 45(3):241-6. PubMed ID: 10845395 [TBL] [Abstract][Full Text] [Related]
14. Limits to the "benefits" from our oncologic interventions: a case report. Markman M Gynecol Oncol; 2000 Aug; 78(2):261-2. PubMed ID: 10926815 [TBL] [Abstract][Full Text] [Related]
15. High dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: results of a pilot study. Sweetenham JW; McKendrick JJ; Jones DH; Whitehouse JM; Williams CJ Br J Cancer; 1990 Feb; 61(2):319-22. PubMed ID: 2155645 [TBL] [Abstract][Full Text] [Related]